02nd week of 2009 patent applcation highlights part 42 |
Patent application number | Title | Published |
20090011410 | METHOD FOR TAILORING ADMINISTRATION OF DRUGS BY QUANTITATION OF MRNA - The present invention discloses a method for tailoring drug protocols to individual patients based on the levels of marker mRNA measured in leukocytes after stimulation of whole blood of the patient with candidate drugs. A method of measuring a patient's responsiveness to a drug is disclosed that includes exposing whole blood of the patient to the drug for 7 hours or less; after the exposure, measuring the amount of an mRNA associated with an effect of the drug in blood cells; and identifying responsiveness to the drug based on the results of the measurement, wherein a change in the amount of the mRNA indicates the patient's responsiveness to the drug. The amount of mRNA measured in the blood cells may be compared with the level of mRNA present in the cells before exposure or with the level of mRNA present in cells exposed for the same amount of time to a control vehicle. Marker mRNAs useful in the present invention include mRNAs encoding the gene product of the p21, BAX, PUMA, NOXA, and IL-2 genes. The method may be employed for patients with, among other conditions, cancer or diseases or conditions requiring immunosuppression. | 2009-01-08 |
20090011411 | Method for Detecting and Quantifying Endogenous Wheat Dna Sequence - It is an object of the present invention to provide partial sequences of endogenous wheat DNA (genome) which are single copies and which allow wheat to be specifically detected without cross-reacting with other plants in PCR, and to provide primers for amplifying these partial sequences, along with a good method for detecting and quantifying endogenous DNA using these primers. The present invention provides, in a method for detecting or quantifying an endogenous wheat DNA sequence in a test sample by means of a polymerase chain reaction, a method comprising a step of using a nucleic acid in the test sample or a nucleic acid extracted from the test sample as a template to amplify the nucleic acid of a region comprising at least 80% or more of a nucleotide sequence represented by one of SEQ ID NO:1 through SEQ ID NO:7 using a primer pair capable of amplifying that region, and a step of detecting or quantifying the amplified nucleic acid. | 2009-01-08 |
20090011412 | HIP1 cancer markers - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, HIP | 2009-01-08 |
20090011413 | Method for screening colon cancer cells and gene set used for examination of colon cancer - Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37. | 2009-01-08 |
20090011414 | HUMAN AUTISM SUSCEPTIBILITY GENE ENCODING A KINASE AND USES THEREOF - The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MARK1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MARKI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia. | 2009-01-08 |
20090011415 | REGULATION OF NEURONAL EXPRESSION OF APOLIPOPROTEIN E - The present invention provides nucleic acids comprising a nucleotide sequence encoding an apolipoprotein E (apoE) splice variant, e.g., an unprocessed apoE, that retains intron 3; and vectors and host cells comprising same. The present invention further provides screening methods to identify agents that inhibit cleavage of intron-3 from the apoE splice variant. The present invention further provides methods of treating apoE-related neurological disorders, involving administering an agent that inhibits removal of intron-3 from a precursor apoE mRNA. | 2009-01-08 |
20090011416 | Random array DNA analysis by hybridization - The invention relates to methods and devices for analyzing single molecules, i.e. nucleic acids. Such single molecules may be derived from natural samples, such as cells, tissues, soil, air and water without separating or enriching individual components. In certain aspects of the invention, the methods and devices are useful in performing nucleic acid sequence analysis by probe hybridization. | 2009-01-08 |
20090011417 | Testing Device - The invention provides, in different aspects, a system, sample preparation device, sample processing cartridge, kit, methods of use, business methods, and computer program product. | 2009-01-08 |
20090011418 | FUNCTIONAL TOLL-LIKE RECEPTORS (TLR) ON MELANOCYTES AND MELANOMA CELLS AND USES THEREOF - The invention relates to a method of detecting Toll-like receptor (TLR) gene expression or protein activity in a melanocyte or melanoma cell. Also disclosed are a method of modulating TLR gene expression or protein activity in a melanocyte or melanoma cell by contacting the cell with a TLR modulating agent and a method of inhibiting melanoma cell migration (e.g., spreading) by contacting the cell with a TLR inhibitor. | 2009-01-08 |
20090011419 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 2009-01-08 |
20090011420 | SPARSELY CROSS-LINKED NANOGELS: A NOVEL POLYMER STRUCTURE FOR MICROCHANNEL DNA SEQUENCING - The present invention is generally directed to novel polymeric materials for use in the electrophoretic separation of nucleic acids. In particular, the novel polymer materials are sparsely crosslinked nanogels, dissolved in an aqueous buffer to form solutions with moderate to high viscosity. The present invention further provides methods for generating such novel polymers, and related methods of their use. | 2009-01-08 |
20090011421 | SUSCEPTIBILITY TO BONE DAMAGE - In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associated with susceptibility to bone damage. In some embodiments, the methods comprise screening for elevated levels of homocysteine in a subject, wherein elevated levels of homocysteine are associated with an increased risk of bone damage. The methods of the invention may be used in predicting the response of a patient to treatment. Also provided are methods for prevention or reducing the risk of bone damage in a subject. | 2009-01-08 |
20090011422 | METHODS FOR CLONING SMALL RNA SPECIES - This invention pertains to methods for cloning microRNA (miRNA) and other small ribonucleic acid (RNA) species from relevant cell sources. | 2009-01-08 |
20090011423 | GENES FOR PROGNOSIS OF CANCER - To provide a novel method for determining the risk of lymph node metastasis of breast cancer uses as an index the difference in the expression levels of marker genes between metastatic breast cancer tissue (or cell) and non-metastatic breast cancer tissue (or cell). The method involves ( | 2009-01-08 |
20090011424 | Cancer-suppressing agents - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein or a homologous protein thereof. | 2009-01-08 |
20090011425 | Incubation Device for Serology and Histology Slides - This application relates to an incubation device for serology or histology supports. It also relates to any apparatus comprising one such device, and to the use of said apparatuses and/or devices in analysis or diagnosis methods. | 2009-01-08 |
20090011426 | Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor - The present invention provides diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by | 2009-01-08 |
20090011427 | ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate. | 2009-01-08 |
20090011428 | Fluid Membrane-Based Ligand Display System for Live Cell Assays and Disease Diagnosis Applications - A supported membrane based, strategy for the presentation of soluble signaling molecules to living cells is described. In this system, the fluidity of the supported membrane enables localized enrichment of ligand density in a configuration reflecting cognate receptor distribution on the cell surface. Display of a ligand in non-fluid supported membranes produces significantly less cell adhesion and spreading, thus demonstrating that this technique provides a means to control functional soluble ligand exposure in a surface array format. Furthermore, this technique can be applied to tether natively membrane-bound signaling molecules such as ephrin A1 to a supported lipid bilayer. Such a surface can modulate the spreading behavior of metastatic human breast cancer cells displaying ligands and biomolecules of choice. The SLB microenvironment provides a versatile platform that can be tailored to controllably and functionally present a multitude of cell signaling events in a parallel surface array format. | 2009-01-08 |
20090011429 | Diagnosis of Pre-Eclampsia - The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (P1GF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin. | 2009-01-08 |
20090011430 | ELECTRICAL DETECTION USING CONFINED FLUIDS - A device having: a laminar flow channel for liquids; two or more electrodes; a confining fluid inlet; a sample inlet; and a meter for measuring the impedance of any fluid between the electrodes. The device may have one or more specific binding sites, or it may have sheathing and unsheathing fluid transporting structures. A method of: providing the device; flowing a confining fluid and a conductive liquid that may contain cells or particles through the channel as described herein; and measuring the impedance between the electrodes. | 2009-01-08 |
20090011431 | Diagnosis of Sepsis by the Selective Determination of the Concentration of Cu/Zn Superoxide Dismutase (Cu/Zn Sod) in Patient Samples - The present invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD) in a serum sample or plasma sample of the patient is selectively determined, and quantitatively or semi-quantitatively measured concentrations, which exceed a predetermined threshold value are correlated with a high risk of mortality. | 2009-01-08 |
20090011432 | Detecting and Profiling Molecular Complexes - Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex. | 2009-01-08 |
20090011433 | RECOMBINANT BIOTIN CARBOXYLASE DOMAINS FOR IDENTIFICATION OF ACETYL CoA CARBOXYLASE INHIBITORS - A peptide comprising an Acetyl CoA carboxylase (ACCase) having a deleted biotin binding domain, having a deleted carboxy transferase domain, and having a functional biotin carboxylase (BC) domain is described. A nucleic acid that encodes the peptide described above and a recombinant host cell that contains the nucleic acid and expresses the encoded peptide is also described. A method of identifying Acetyl CoA carboxylase inhibitors, fungicides, herbicides and pharmaceuticals is also described herein. | 2009-01-08 |
20090011434 | Methods And Compositions For Diagnosing Breast Cancer - Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin. | 2009-01-08 |
20090011435 | ASSAYS FOR DETECTING ANTIBODIES TO THERAPEUTICS - The disclosed invention relates to methods and devices for detecting a biologic in a test sample. In particular, the disclosed assay utilizes EPO as a target to detect endogenous anti-EPO antibodies in a sample and does not manipulate or modify the target EPO antibody. | 2009-01-08 |
20090011436 | Dry Chemistry, Lateral Flow-Reconstituted Chromatographic Enzyme-Driven Assays - A lateral flow chromatographic assay format for the performance of rapid enzyme-driven assays is described. A combination of components necessary to elicit a specific enzyme reaction, which are either absent from the intended sample or insufficiently present therein to permit completion of the desired reaction, are predeposited as substrate in dry form together with ingredients necessary to produce a desired color upon occurrence of the desired reaction. The strip is equipped with a sample pad placed ahead of the substrate deposit in the flowstream, to which liquid sample is applied. The sample flows from the sample pad into the substrate zone where it immediately reconstitutes the dried ingredients while also intimately mixing with them and reacting with them at the fluid front. The fluid front moves rapidly into the final “read zone” wherein the color developed is read against predetermined color standards for the desired reaction. Pretreatment pads for the sample, as needed, (e.g. a lysing pad for lysing red blood cells in whole blood) are placed in front of the sample pad in the flow path as appropriate. The assay in the format of the invention is faster and easier to perform than analogous wet chemistry assays. | 2009-01-08 |
20090011437 | Methods of Detecting Antibodies Specific for Denatured HLA Antigens - The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ. | 2009-01-08 |
20090011438 | Collagen VI and Cancer - Methods of determining whether a cancer is progressing by measuring surface-bound collagen VIα3 are provided. Also provided are methods of identifying hyperplasia in a tissue by measuring surface-bound collagen VIα3. Additionally, methods of identifying carcinoma in a tissue by measuring surface-bound collagen VIα3 are provided. Further provided are methods of imaging carcinoma in a tissue by staining the tissue with a specific binding partner to collagen VIα3. Methods of treating a cancer by preventing binding of collagen VIα3 onto cells of the cancer are additionally provided. | 2009-01-08 |
20090011439 | Prognosis and Therapy Predictive Markers and Methods of Use - Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention. | 2009-01-08 |
20090011440 | Receptor Tyrosine Kinase Signaling Pathway Analysis For Diagnosis And Therapy - The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis. | 2009-01-08 |
20090011441 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE - Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment. | 2009-01-08 |
20090011442 | TB diagnostics based on mycobacterium tuberculosis excretory secretory antigens and their specific immunoglobulins - The present invention relates to isolation and identification of novel | 2009-01-08 |
20090011443 | METHODS FOR SIMULTANEOUSLY DETECTING BOTH MEMBERS OF A BINDING PAIR - Methods and kits for simultaneously measuring both members of a binding pair are described. | 2009-01-08 |
20090011444 | DETECTION AND DIAGNOSIS OF INFLAMMATORY DISORDERS - Soluble H4 (sH4) levels have been discovered to correlate with the stage or severity of inflammatory disorders including autoimmune disorders. In particular, circulating levels of sH4 can be used as a diagnostic for determining the severity of an inflammatory disorder or the propensity for developing an inflammatory disorder. The severity of an inflammatory disorder can be determined by assaying the levels of sH4 in a subject and comparing the levels of sH4 to reference sH4 concentrations that correlate to specific stages of an inflammatory disorder. The therapeutic efficacy of treatments for inflammatory disorders can also be determined by comparing levels of sH4 before and during treatment. Methods and devices for measuring sH4 are also provided. | 2009-01-08 |
20090011445 | METHOD AND APPARATUS FOR IN VIVO COLLECTION OF CIRCULATING BIOLOGICAL COMPONENTS - The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe. | 2009-01-08 |
20090011446 | COLONY ASSAY MINIATURIZATION WITH ENUMERATION OUTPUT - A system combining a clonogenic differentiation assay with an instrument-based ATP bioluminescence proliferation assay to produce a standardized colony-forming stem and progenitor cell potency assay is provided. | 2009-01-08 |
20090011447 | QUANTIFICATION OF VITELLOGENIN - The present invention is directed to a simple method for absolute quantification of plasma vitellogenin from two or more different fish species such as Rainbow trout and Atlantic salmon, or Atlantic cod and haddock. In the case of Rainbow trout and Atlantic salmon, plasma samples obtained from control and β-estradiol induced fish were digested with trypsin. A characteristic ‘signature peptide’ was selected and analyzed by high performance liquid chromatography coupled to an electrospray quadrupole-time-of-flight tandem mass spectrometer, using a deuterated homologue peptide as an internal standard. The hybrid tandem mass spectrometer was operated in a ‘pseudo’ selected reaction monitoring mode by which three diagnostic product ions were monitored for identification and quantification purposes. The reproducibility (coefficient of variation ˜5%) and sensitivity (limit of quantification of 0.009 mg/mL) achieved by this simple assay allow it to be considered as an alternative to immunological assays. In the case of Atlantic cod and haddock, the amino acid sequence of the vitellogenin protein has not yet been determined, but, the Atlantic cod vitellogenin has been characterized using a ‘bottom-up’ mass spectrometric approach. Vitellogenin synthesis was induced ‘in vivo’ with β-Estradiol, and subjected to trypsin digestion for characterization by matrix-assisted laser desorption/ionization-Quadrupole-Time-of-flight tandem mass spectrometry. A peptide mass fingerprint was obtained and ‘de novo’ sequencing of the most abundant tryptic peptides was performed by low energy collision induced dissociation-tandem mass spectrometry. Thus, the sequences of various tryptic peptides have been elucidated. It has also been determined that Atlantic cod vitellogenin shares a series of common peptides with the two different known vitellogenin sequences of Haddock, a closely related species. There are also disclosed novel isolated signature peptides, namely Thr-Tyr-Phe-Ala-Gly-Ala-Ala-Ala-Asp-Val-Leu-Glu-Val-Gly-Val-Arg, Asp Leu Gly Leu Ala Tyr Thr Glu Lys, Phe Phe Gly Gln Glu Ile Ala Asn Ile Asp Lys, Glu Ile Val Leu Leu Gly Tyr Gly Thr Met Ile Ser Lys and Tyr Glu Ser Phe Ala Val Ala Arg. | 2009-01-08 |
20090011448 | PRETREATMENT AGENT FOR LIMULUS TEST - A pretreatment agent for a sample to be subjected to Limulus assay comprising an alkali metal sulfate and/or an alkaline earth metal sulfate wherein the sulfate(s) has a final concentration of 20 mM or more when the sulfate(s) is allowed to contact with the sample, or an alkali metal halide and/or an alkaline earth metal halide wherein the halide(s) has a final concentration of from 0.4 M to 1.2 M or less when the halide(s) is allowed to contact with the sample, or a kit for Limulus assay reagent comprising thereof as a composing article. | 2009-01-08 |
20090011449 | NO CALIBRATION ANALYTE SENSORS AND METHODS - A meter and sensors, for use in combination, where no calibration code has to be entered by the user or is read by the meter. The meter is configured with a predetermined slope and y-intercept built into the meter. If the slope and y-intercept of the sensor are within a predetermined area or grid, or otherwise close to the slope and y-intercept of the meter, the batch of sensors is acceptable for use with that meter for providing accurate analyte concentration results. | 2009-01-08 |
20090011450 | Dry analytical element for lipase measurement - It is an object of the present invention to provide a dry analytical element for pancreatic lipase analysis having high selectivity with respect to pancreatic lipase, whose multianalyte correlation has been improved. The present invention provides a dry analytical element for measurement of pancreatic lipase contained in a body fluid, which comprises at least one development layer and/or reagent layer containing diglyceride or triglyceride of long-chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerine measurement reagent, wherein the development layer and/or the reagent layer comprise two or more types of anionic surfactants and at least one type of the anionic surfactant is alkylarylsulfonate. | 2009-01-08 |
20090011451 | MICROFLUIDIC DEVICE AND LEUCOCYTE ANTIGEN MEDIATED MICROFLUIDIC ASSAY - The present invention relates to an leucocyte antigen mediated microfluidic assay and a microfluidic device for analyzing a subjects' body fluids containing leucocytes to determine if the subject has been previously exposed to a predetermined antigen. | 2009-01-08 |
20090011452 | Method of Prognosis of Mental Diseases, E.G. Autism and Cerebral Palsy - The invention provides a method of prognosis for applied behavioral analysis treatment of mental disease, in particular autism or cerebral palsy, in a human subject. The method includes analyzing a sample of body tissue or fluid from the subject for the presence or absence of a chemical marker indicative of the likelihood of success or failure of applied behavioral analysis treatment of the mental disease, and optionally, based on the analysis, beginning, continuing or ceasing applied behavioral analysis treatment of the subject. The sample is preferably an urine sample, and the preferred prognostic markers are: gluten derivatives, indolyl-3-acryloylglycine (IAG), serotonin uptake stimulator, β-casomorphineamides, gliadinomorphine, β-casomorphines, deltorphins, Demorphine, glutemorphine, gluten exophins, compounds of molecular weight of 687 Daltons. | 2009-01-08 |
20090011453 | Methods for Producing Proteins Using Hamster Igf-1 - A polypeptide selected from the group consisting of: (1) a polypeptide having the amino acid sequence of SEQ ID NO: 1, and (2) a polypeptide having an amino acid sequence in which the third amino acid of the amino acid sequence of SEQ ID NO: 1 is substituted by another amino acid and having insulin-like growth factor 1 (IGF-1) activity; a DNA encoding said polypeptide; a vector containing said DNA; a host cell containing said vector; and a method for preparing a recombinant protein using said polypeptide. | 2009-01-08 |
20090011454 | Fluorescent Sensors for Cellular Amines - The invention provides compounds of formulas I, II, and III, methods of making them, and methods of their use. The compounds of the invention can be used as fluorescent sensors, for example, to detect an amine-containing analyte in a biological sample. The compounds can be selective for one type of amine over others and the amount of fluorescence can be correlated with the concentration of the amine in the sample. | 2009-01-08 |
20090011455 | DISEASE MODEL INCORPORATION INTO AN ARTIFICIAL IMMUNE SYSTEM (AIS) - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response. | 2009-01-08 |
20090011456 | Methods for the Diagnosis and Prognosis of Graft Versus Host Disease By Measurement of Peripheral Cd3+Cd4+Cd8Beta+ Cells - Acute graft versus host disease (GvHD) is one of the most significant clinical problems in allogeneic blood and marrow transplantation. Currently, there is no unequivocal diagnostic test for GvHD until the disease is well developed and can be recognized histologically. The invention provides a blood based test for diagnosis and/or prognosis of GvHD, allowing assessment of risk for developing GvHD prior to appearance of clinical symptoms. Using flow cytometry, peripheral blood mononuclear cells are assessed for an increase in proportion and fluctuation of CD3 | 2009-01-08 |
20090011457 | Method and device for testing the bactericidal effect of substances - The method for checking the degree of microbial loading of laundry after a wash cycle is characterized in that a defined amount of living microorganisms are washed together with the laundry, in that the number of microorganisms still living after the end of the wash process is determined and in that the effectiveness or quality of the wash process is determined from the difference between the original amount of living microorganisms and the amount of microorganisms which still remain alive after the wash process. A device for carrying out this method comprises inter alia a container ( | 2009-01-08 |
20090011458 | Method for selectively staining microorganisms - A method for selectively flagging target microorganisms in a liquid sample also including background particles comprises the steps of adding a lysing agent selected to breach the background particles to the sample, adding a dye selected to flag the target microorganisms to the sample, adding a suppressing agent selected to penetrate the breached background particles and suppress the dye within the breached background particles to the sample, and measuring the flagged target microorganisms in the sample. The method is particularly useful in organic samples such as dairy and blood product solutions. | 2009-01-08 |
20090011459 | Process for producing functional non-naturally occurring proteins, and method for site-specific modification and immobilization of the proteins - There is provided a process for industrial production of non-naturally occurring proteins composed of less than 20 amino acids, wherein the proteins retain their original functions while being capable of site-specific modification or immobilization, or having new functions not found in nature in addition to the original functions of the proteins. | 2009-01-08 |
20090011460 | Calcium-binding photoprotein, gene encoding the same, and use thereof - A protein according to the invention can be used to detect or measure calcium ions is provided. Further the protein is useful as a reporter protein or a luminescence marker. A polynucleotide according to the invention is also useful as a reporter gene. | 2009-01-08 |
20090011461 | Human Spasmolytic Polypeptide in Glycosylated Form - Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr | 2009-01-08 |
20090011462 | Polypeptides having Lipase Activity and Polynucleotides Encoding Same - The present invention relates to polypeptide having lipase activity and which further has a RP of at least 0.8 and a BR of at least 1.1 at the test conditions given in the specification. | 2009-01-08 |
20090011463 | Pcka Modifications and Enhanced Protein Expression in Bacillus - The present invention provides cells that have been genetically manipulated to have an altered capacity to produce expressed proteins, wherein the pckA gene has been modified or deleted. In particular, the present invention relates to Gram-positive microorganisms, such as | 2009-01-08 |
20090011464 | Humanized immunoglubulin reactive with alph4beta7 integrin - The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α4β7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for α4β7 integrin. | 2009-01-08 |
20090011465 | INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES - The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids. | 2009-01-08 |
20090011466 | CONCATAMERIC IMMUNOADHESION MOLECULE - Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form. | 2009-01-08 |
20090011467 | NOVEL FRUCTOSYL PEPTIDE OXIDASE - The present invention has an object of providing a novel fructosyl peptide oxidase having superior physicochemical properties such as stability that is useful as an enzyme for clinical diagnosis, and an object of providing a method for producing the fructosyl peptide oxidase. | 2009-01-08 |
20090011468 | Method for improving protein production - The present invention relates to the production of proteins in a cell or host cell. The invention uses a TRAnscription Pause (TRAP) sequence to enhance a protein expression characteristic of a protein expression unit. The TRAP sequence is thought to prevent, at least in part, formation of antisense RNA or to, at least in part, prevent transcription to enter the protein expression unit. In one embodiment, the invention provides a method for expression of at least one protein of interest in a cell comprising providing the cell with at least one protein expression unit that comprises a promoter functionally linked to an open reading frame encoding at least one protein of interest, characterized in that the protein expression unit further comprises at least one TRAP sequence and wherein the TRAP sequence is functionally located downstream of the open reading frame and at least in part prevents formation of antisense RNA. In another embodiment, the TRAP sequence is functionally located upstream of the promoter and at least in part prevents transcription to enter the expression unit. Preferably, the expression protein unit further comprises at least one STabilizing Anti-Repressor sequence. | 2009-01-08 |
20090011469 | METHOD AND FORMULATION FOR THE EXTRACTION OF NUCLEIC ACIDS FROM ANY COMPLEX STARTING MATERIALS - The invention relates to a universal and greatly simplified method as well as a composition for isolating nucleic acids from different starting materials containing nucleic acids. The composition contains at least one buffer solution for proteolytically solubilizing biological samples, the buffer containing no chaotropic or antichaotropic component, at least one alcoholic component and/or a detergent, a solid phase, and a wash and elution buffer. | 2009-01-08 |
20090011470 | Nucleic acid sample preparation by exclusion of DNA - Devices and methods are provided for separation of nucleic acids from waste materials in a biological sample, and then reacting the separated nucleic acids. In some embodiments, the methods comprise mixing a cell lysate having nucleic acids and waste materials with a waste-binding matrix to capture the cellular waste materials from the lysate. The waste-binding matrix can comprise hydrophilic and/or hydrophobic size-exclusion, ion-exchange particles. In some embodiments, the device comprises a substrate comprising a fluid processing pathway in which nucleic acid sample preparation occurs prior to a downstream genotyping reaction. | 2009-01-08 |
20090011471 | Engineered plasmids and their use for in situ production of genes - Nucleic acid sequences encoding at least a portion of a polypeptide are directly incorporated into a plasmid by DNA polymerization or reverse transcription of a nucleic acid template. In particularly preferred embodiments, nucleic acid sequences encoding at least a portion of an antibody are directly incorporated into a plasmid by reverse transcription of messenger RNA (mRNA). | 2009-01-08 |
20090011472 | ISOTHERMAL DNA AMPLIFICATION - Provided herein are nucleic acid synthesis methods and agents that employ an endonuclease for example, endonuclease V, to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of the target DNA. | 2009-01-08 |
20090011473 | Saccharifying cellulose - Dissolution, partial dissolution or softening of cellulose in an ionic liquid (IL) and its subsequent contact with anti-solvent produces regenerated cellulose more amorphous in structure than native cellulose, which can be separated from the IL/anti-solvent mixture by mechanical means such as simple filtration or centrifugation. This altered morphology of IL-treated cellulose allows a greater number of sites for enzyme adsorption with a subsequent enhancement of its saccharification. The IL-treated cellulose exhibits significantly improved hydrolysis kinetics with optically transparent solutions formed after about two hours of reaction. This provides an opportunity for separation of products from the catalyst (enzyme) easing enzyme recovery. With an appropriate selection of enzymes, initial hydrolysis rates for IL-treated cellulose were up to two orders of magnitude greater than those of untreated cellulose. Due to the non-volatility of the IL, anti-solvent can be easily stripped from the IL/anti-solvent mixture for recovery and recycle of both the ionic liquid and anti-solvent. | 2009-01-08 |
20090011474 | Process for producing sugars from cellulosic biomass - A process for increasing production of sugars from cellulose in a plant biomass using ammonia after swelling of the biomass with water and enzymatic hydrolysis is described. The sugars are preferably fermented to an alcohol, particularly ethanol as a fuel for vehicles. | 2009-01-08 |
20090011475 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof - Disclosed is a method for production of an optically active biphenylalanine compound represented by the formula (2): | 2009-01-08 |
20090011476 | GENE CLUSTER AND METHOD FOR THE BIOSYNTHESIS OF TERREQUINONE A - The present invention provides a novel gene cluster containing five genes (tdiA-E) involved in indole alkaloid synthesis. Disruption of tdiB, encoding an enzyme with prenyltransferase activity, transferring dimethylallylpyrophosphate to C-2 of an indole structure, eliminated the production of the antitumor compound terrequinone A, a metabolite not known from | 2009-01-08 |
20090011477 | Stability of Secondary Metabolite Mass Production Through Synchronized Plant Cell Cultures - This invention is a method of minimizing the variation of cell growth and production through homogeneous cell line development. To be more specific, it is the method of isolating and proliferating single cell clone from the procambium to promote the stability of the plant-derived biologically active substances production by solving the problems of decrease in cell growth and the productivity during the long term culture. | 2009-01-08 |
20090011478 | Biochemical Synthesis of 1,4-Butanediamine - The invention relates to a process for biochemical synthesis of 1,4-butanediamine in a microorganism having an increased level of an ornithine decarboxylase activity (increased ODC activity) as compared to the native level of the ornithine decarboxylase activity, wherein in the microorganism also an increased activity of N-acetylglutamate formation is present as compared to the native level of activity of N-acetylglutamate formation in the microorganism and wherein 1,4-butanediamine produced in the microorganism is excreted into a fermentation broth, and is recovered from the fermentation broth. The invention also relates to vectors, plasmids and hosts carrying a corresponding increased ODC activity and an increased activity of N-acetylglutamate formation. | 2009-01-08 |
20090011479 | Biotransformation of colchicinoid compounds - The present invention relates to a biotransformation process, effected by means of selected microbial strains, for the preparation of 3-O-glycosyl derivatives of colchicinoid compounds. | 2009-01-08 |
20090011480 | Use of Cellulosic Materials for Cultivation of Microorganisms - The invention provides methods of cultivating oil-bearing microbes using cellulosic material. Also provided are microorganisms that manufacture non-alcohol-based fuels and fuel feedstocks through a process of converting cellulosic materials into oils. Also provided are compositions comprising depolymerized cellulosic materials and oil-bearing microbes. Some methods of microbial fermentation are provided that comprise combining depolymerized cellulosic materials with other non-cellulosic feedstocks to enhance the economics of renewable fuel manufacturing. Particular advantages of the processes provided herein include production of oils rather than alcohols through cellulosic processes. Additional advantages include methods for manufacturing high nutrition oils from non-edible feedstocks such as wood chips, switchgrass, and bagasse. | 2009-01-08 |
20090011481 | PROCESS FOR FERMENTING SUGARS CONTAINING OLIGOMERIC SACCHARIDES - Sugar mixtures containing nonfermentable oligomers are fermented in the presence of certain enzymes that depolymerise the oligomers simultaneously with the fermentation process. | 2009-01-08 |
20090011482 | Process For Producing Glycolic Acid From Formaldehyde And Hydrogen Cyanide - A process is provided for producing glycolic acid from formaldehyde and hydrogen cyanide. More specifically, heat-treated formaldehyde and hydrogen cyanide are reacted to produce glycolonitrile having low concentrations of impurities. The glycolonitrile is subsequently converted to an aqueous solution of ammonium glycolate using an enzyme catalyst having nitrilase activity derived from | 2009-01-08 |
20090011483 | Process For Producing Glycolic Acid From Formaldehyde And Hydrogen Cyanide - A process is provided for producing glycolic acid from formaldehyde and hydrogen cyanide. More specifically, heat-treated formaldehyde and hydrogen cyanide are reacted to produce glycolonitrile having low concentrations of impurities. The glycolonitrile is subsequently converted to an aqueous solution of ammonium glycolate using an enzyme catalyst having nitrilase activity derived from | 2009-01-08 |
20090011484 | CONCURRENT SACCHARIFICATION AND FERMENTATION OF FIBROUS BIOMASS - A process for simultaneous saccharification and fermentation of a cellulosic solids fraction extracted from a lignocellulosic feedstock. The viscosity of the cellulosic solids fraction is reduced by intermixing with a liquid carbohydrate stream. A suitable liquid carbohydrate stream is a de-lignified liquids fraction that was previously separated from the solids fraction during processing of the lignocellulosic feedstock. Alternatively, the viscosity of the solids fraction may be reduced by commingling with a liquid carbohydrate stream comprising one or more monosaccharides. The reduced-viscosity cellulosic solids fraction is then commingled with a fermentative microbial inoculant and a cellulosic biomass-degrading enzyme composition. The commingled mixture is maintained in a pressurized reaction vessel under elevated temperatures to enable simultaneous enzymatic hydrolysis of the cellulosic solids to monosaccharides and fermentation of the monosaccharides to produce an ethanolic beer. The ethanolic beer is distillable for recovery of fuel-grade ethanol and a stillage that may be further processed. | 2009-01-08 |
20090011485 | METHOD OF RETROVIRUS STORAGE - A method of retrovirus storage, characterized in that a retrovirus is sustained in the presence of a substance with retrovirus binding activity immobilized on a solid phase. Further, there is provided a retrovirus composition characterized in that a retrovirus in the form of binding to a substance with retrovirus binding activity is sealed in a container holding a solid phase having the substance with retrovirus binding activity immobilized thereon. | 2009-01-08 |
20090011486 | Biodegradable Elastomers - The present inventions in various aspects provide elastic polymers compositions for encapsulation of cells. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked in the presence of glycerol and a population of cells to form elastic porous polymer scaffolds suitable for cell encapsulation and/or proliferation. | 2009-01-08 |
20090011487 | Production of UGPPase - What are disclosed are a purified novel enzyme protein, UGPPase, which naturally occurs in animal cells, its production by means of recombinant technology, an antibody to the enzyme protein, a method of carrying out ELISA for measurement of the amount of UGPPase in an analyte and a method for determination of UDPG in a sample. The one-way enzyme protein catalyses hydrolysis of UDP-glucose, the precursor molecule of glycogen, into glucose-1-phosphate (G1P) and uridine 5′-monophosphate (UMP). | 2009-01-08 |
20090011488 | METHODS FOR STORING COMPOSITIONS USEFUL FOR SYNTHESIZING NUCLEIC ACID MOLECULES - In one aspect, the present invention provides methods for storing a composition useful for synthesizing nucleic acid molecules. The methods of this aspect of the invention include the steps of: (a) freezing multiple aliquots of a liquid composition comprising from 1000 units/mL to 5000 units/mL of a reverse transcriptase, or from 10,000 units/mL to 50,000 units/mL of an RNA polymerase, wherein the multiple aliquots of the liquid composition are disposed within multiple receptacles defined by a container body; and (b) a step selected from the group consisting of (1) storing the frozen aliquots at a temperature below −15° C., and (2) drying the frozen aliquots to produce dried aliquots of the composition, wherein each dried aliquot of the composition comprises an amount of water that is less than 0.1% by weight of the dried aliquot, and storing the dried aliquots at a temperature below −15° C. | 2009-01-08 |
20090011489 | MULTIPLY-SUBSTITUTED PROTEASE VARIANTS - Novel enzyme variants including protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease, Such variant proteases have properties which are different from those of the precursor protease, such as altered wash performance. The substituted amino acid residue correspond to positions 27, 45, 170, 181, 251 and 271 of | 2009-01-08 |
20090011490 | IMMUNOGENIC MINICELLS AND METHODS OF USE - The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject. | 2009-01-08 |
20090011491 | Culture Media for Increasing Biopesticide Producing Microorganism's Pesticidal Activity, Methods of Producing Same, Biopesticide Producing Microorganisms so Produced - A media for growing a biopesticide producing microorganism comprising waste water sludge having undergone thermal alkaline hydrolysis performed by adjusting the pH of the wastewater sludge between about 8 and about 12 with an alkaline solution selected from the group consisting of NaOH, KOH, CaOH | 2009-01-08 |
20090011492 | Photobioreactor Cell Culture Systems, Methods for Preconditioning Photosynthetic Organisms, and Cultures of Photosynthetic Organisms Produced Thereby - Certain embodiments of the invention involve methods and systems for preselecting, adapting, and preconditioning one or more species of photosynthetic organisms, such as algae, to specific environmental and/ or operating conditions to which the photosynthetic organisms will subsequently be exposed during utilization in a photobioreactor apparatus of a gas treatment system. Also disclosed are new algal strains and cultures that can be produced by practicing the preselection, adaption, and preconditioning methods. | 2009-01-08 |
20090011493 | DEVICE CONTAINING CYTOPHILIC ISLANDS THAT ADHERE CELLS SEPARATED BY CYTOPHOBIC REGIONS - The invention provides a device for adhering cells in a specific and predetermined position, and associated methods. The device includes a plate defining a surface and a plurality of cytophilic islands that adhere cells, isolated by cytophobic regions to which cells do not adhere, contiguous with the cytophilic islands. The islands or the regions or both may be formed of a self-assembled monolayer (SAM). | 2009-01-08 |
20090011494 | Method for controlling biological function with mechanical vibration and device therefor - Methods and apparatus for controlling biological functions with mechanical vibration are provided. Stimulation is applied to cells of one of an organism, bacteria or virus by mechanical vibration. The biological function comprises biological functions relating to cell growth. The biological functions relating to cell growth may include at least one of cell cultivation, cell proliferation, cell fusion, and cell differentiation. | 2009-01-08 |
20090011495 | Incubator Apparatus and Method - The present invention relates to a method of processing analyte using a portable incubator apparatus. The incubator apparatus | 2009-01-08 |
20090011496 | Enhancement of mammalian embryo development - A method of enhancing in vitro development of a mammalian embryo is disclosed which comprises supplementing the culture medium with a prostaglandin, or a prostaglandin analog, in an amount effective to promote complete hatching of the embryo (i.e., freeing of the embryo from the zona pellucida). The quality of human blastocysts is enhanced in vitro by culturing with a prostacyclin agonist, Iloprost. The in vivo implantation potential and live birth potential of an in vitro fertilization embryo is thereby enhanced and establishment of a viable pregnancy is facilitated. | 2009-01-08 |
20090011497 | Peptides and related compounds having thrombopoietic activity - The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal. | 2009-01-08 |
20090011498 | EXPANSION OF NK CELLS AND THERAPEUTIC USES THEREOF - The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells. | 2009-01-08 |
20090011499 | Antibodies that bind LDCAM - The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides. | 2009-01-08 |
20090011500 | G+C RICH BINDING PROTEIN - A novel transcription regulator of G+C-rich promoters, the murine G+C-rich Promoter Binding Protein (mGPBP), and its interaction pattern with other transcription factors are disclosed. A human homologue of mGPBP, hGPBP, is described as well. | 2009-01-08 |
20090011501 | NOVEL DEATH DOMAIN PROTEINS - In accordance with the present invention, there are provided novel Death Domain (DD), Death Effector Domain (DED) and NB-ARC domain proteins. The invention also provides nucleic acid molecules encoding DD, DED and NB-ARC domain proteins, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs, DEDs or NB-ARC domains. Such DDs, DEDs and NB-ARC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases. | 2009-01-08 |
20090011502 | Pdx1 Expressing Endoderm - Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed. | 2009-01-08 |
20090011503 | Primate Embryonic Stem Cells - A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed. | 2009-01-08 |
20090011504 | Cultured cell construct which contains spheroids of cultured animal cells and the use thereof - Parenchymal cells are cultivated on cultivated endothelial cells or cultivated fibroblasts which have been separated by a surface of a specific hydrophilic polymer, and which have been patterned. A culture which contains thus formed patterned spheroids of cultivated parenchymal cells is thereby provided by this invention. This culture maintains a function which is specific to the parenchymal cells over a long period of time. | 2009-01-08 |
20090011505 | METHOD AND DEVICE FOR THE CRYO-CONSERVATION OF SAMPLES - A method and a device for the cryo-conservation of a hydrous sample, in particular biological sample, wherein the sample is introduced into a cavity of a container, remaining free space of the cavity if any is filled with a hydrous liquid, the cavity is closed in a liquid-tight manner and the container is held in a holding device, and the container together with the sample is cooled to a temperature below 251 K, preferably 173 K, for example by means of liquid nitrogen, propane or ethane, wherein the container and the holding device prevent an expansion of the cavity in volume. The selected cooling rate is sufficiently high so that a crystal formation of the freezing water is suppressed in favor of glass formation. | 2009-01-08 |
20090011506 | APPARATUS AND PROCESS FOR WASHING TISSUE AND/OR CELL - An apparatus for washing cells and/or tissue includes an outer sleeve, an inner assembly, and a filter. The outer sleeve includes a closed end and an open end. The inner assembly is axially movable in the outer sleeve. The filter is affixed to the inner assembly, wherein a chamber is formed by the filter, the outer sleeve, and the inner assembly. Furthermore, a process for washing cells and/or tissue comprising: (a) providing an apparatus as described above, wherein the cells and/or tissue and washing liquid are disposed in the chamber, and (b) axially moving the inner assembly to wash the cells and/or tissue. | 2009-01-08 |
20090011507 | Scaffolds for Use in Tissue Engineering to Culture Cells - In the field of tissue engineering there is a need for a scaffold which is suited to low volume manufacture, and which allows the culture of complex cell structures. A scaffold ( | 2009-01-08 |
20090011508 | Method for the production of a strain having a deleted region in chromosome - The purpose of the present invention is therefore to provide a transformant which will not produce a toxic substance such as Aflatoxin even after being manipulated with genetic engineering by efficiently deleting a large chromosomal region with a length of from several tens to hundreds kb such as a cluster of biosynthesis genes encoding the toxic substances such as Aflatoxin. | 2009-01-08 |
20090011509 | INTEGRASE FUSION PROTEINS AND THEIR USE WITH INTEGRATING GENE THERAPY - In a method of targeting intergration of a transgene comprising retrovirus-like DNA into a eukaryotic genome, the genome is cleared by an endonuclease and the transgene is introduced at the site of cleavage, wherein the endonuclease is specific to a site in an abundant rDNA locus and is fused to an integrase that mediates the introduction of the transgene. The fusion protein may be new. | 2009-01-08 |